Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Total Current Liabilities

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 (BLACR) currently reports a total current liabilities of $18M as of March 2026. That compares with $14M in the prior-year period — up 28.9% year over year. Use the charts on this page to explore Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's total current liabilities history and peer comparisons.

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's total current liabilities increased from $14M to $18M — a 28.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 reported $18M in total current liabilities as of March 2026. That compares with $14M in the prior-year period — up 28.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028, and consider following BLACR for alerts when major investors trade the stock.